IKT

Inhibikase Therapeutics, Inc. is a biotechnology company in the healthcare sector with 15 employees and a market capitalization of $243.75M. As a small player in its industry, Inhibikase operates in the space where medical innovation meets cutting-edge technology. The company's financial health is marked by significant losses, with net income of -$47,657,116 and EBITDA of -$53,076,400 for the trailing 12 months. Its gross margin, operating margin, and profit margin are all at 0.0%, indicating a complete lack of profitability. Returns on equity and assets also reflect this trend, standing at -131.7% and -79.1%, respectively. In terms of its balance sheet, Inhibikase holds $77.32M in cash but has no debt. Inhibikase's valuation metrics paint an uncertain picture. Its forward P/E ratio is -8.04, while the trailing 12-month price to earnings ratio stands at 4.19. The company's price-to-book ratio is 2.49, and its EV/EBITDA ratio is -1.88, all indicating a complex valuation situation. With no dividend yield or payout ratio available, investors may need to focus on the company's growth prospects – which are not provided in the available facts.